NCT00695448View on ClinicalTrials.gov

Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 24, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Solid Tumours
Interventions
DRUG

GSK1059615

GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.

Trial Locations (2)

37203

GSK Investigational Site, Nashville

77030-4009

GSK Investigational Site, Houston

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY